Healthcare groups with good culture & half-decent WLB?

Seems like every HC group on the street these days is either super sweaty, incredibly toxic or both. I'm not asking for a normal life here, but does anyone know where a guy can look to just have some time to breathe in this coverage?

40 Comments
 

Based on the most helpful WSO content, it seems that industry-specific boutiques or middle-market firms that have strong cultures and are not toxic sweatshops are highly recommended. These firms have a ton of healthcare deal flow under $1 billion to go around.

However, it's important to note that the culture and work-life balance can vary greatly even within the same firm, depending on the specific group and the people you work with.

As for larger banks, there have been some mixed reviews. For instance, the healthcare group at JPMorgan has been described as a sweatshop with a high turnover rate, but there are also positive comments about making it into a decent group within the same bank.

Remember, it's not just about finding a group with a good reputation, but also about finding a group where you fit in and can thrive. So, do your due diligence, network, and try to get a feel for the culture and work-life balance of the specific groups you're interested in.

Sources: PJT RSSG Culture?, WSO 2022 Investment Banking Work-Conditions Survey (Part 2/3), Private Equity shops with the best work/life balance, Best healthcare groups?

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

I am curious what makes you say this. Did you/someone you know work there and did they say how many hrs/week they were doing in HC and what culture was like?

 
Most Helpful

Unfortunately healthcare is naturally sweaty due to 1) high dealflow (across services, pharma, tech, outsourcing) and 2) extremely high competition. Every bank has a healthcare team and there are a million healthcare-focused banks (TripleTree, MTS, Cain, Edgemont, etc.). Pitches end up becoming a ton of work because you are competing with pretty much the entire universe (compared to say, FIG or consumer, which have much more limited coverage). 

Also - within pharma / biotech specifically, because most transactions happen at the asset / drug level, and each asset can be transacted in an infinite combination of ways (licensing, royalties, asset sale, PIPE) across geos (Japan, RoW, US, EU, etc.) you just end up having to track a ton of stuff. Idea books end up being 30+ pages because you present so many potential drug targets.  

 


Can you elaborate on what you mean by this? Is the group’s better culture a result of senior attitudes or the fact that most hardos at EVR want to get into the media + telecom/tech groups. Also, does NYC HC have a better stance on working from home? Incoming SA at EVR nyc.

 

I work at a HC focused boutique and this might be one of the most true things I’ve ever read. 

 

Ditto to this. The majority of the firm are a great mix of intellectual minds. Always enjoyed conversing with some of the bankers I know there. Many (not all, but more than most other HC groups) of them really do have a passion about healthcare. Great culture, long hours though. Pay well too. I consider them an industry boutique that is on par with some notable EB HC groups.

 

Houlihan HC. The team legit parties every 3 days and buys bottle service. Awesome culture, street pay. I’d say that’s the best of both worlds

 

For anyone in HC (particularly biotech & pharma) banking, what exit opps are you looking at if you’re deciding to leave IB? It seems like a PhD or MD is a requirement for any Life Sciences VC or Growth fund. Thanks

 


One of the key challenges in biopharma is that everything gets stale very quickly.
There is an insane amount of data coming through. Trial results from a company. Competitive landscape. A deep dive on a single molecule can easily be 20-30 pages.

I get banker’s pitchbooks of 100+ pages regularly. Then you compound that by the complexities (biology, technologies, etc) and the fact that the average analyst doesn’t have a life sciences background.
By comparison, the standard BD exec has a phd + functional experience and focuses on a narrow area. Even equity research analysts for biotech are specialised.

On exits if you work in biopharma: corporate development (not BD) in the larger companies work well. In smaller companies too because there usually a split between the evaluation team (i.e. leads the scientific evaluation) and the transaction piece. Scientists are great at assessing a molecule, but bankers are better at working through deal dynamics.

 

Eligendi aut corporis qui ea consequuntur itaque minus. Laudantium nihil perferendis similique nihil ea sed qui. Omnis sint illum pariatur officia dolor dolorum. Ab consequatur dolor voluptates beatae nisi non facilis quaerat. Unde unde excepturi soluta totam.

Blanditiis amet ipsa laborum rerum repudiandae. Incidunt minima nihil quam sit. Id sapiente eligendi explicabo. Harum voluptas dolores praesentium exercitationem voluptatem aspernatur.

 

Quibusdam excepturi illum quisquam aperiam fuga esse nobis. Velit in aut cumque dolorem aut ut aspernatur. Quia possimus accusantium aut praesentium fugiat. Et quo pariatur excepturi voluptas aspernatur dolorum qui. Dolorum et ea et doloremque iure.

Est explicabo est omnis. Repudiandae doloribus laboriosam omnis dolorem vel dolorum. Quidem omnis voluptas assumenda laudantium voluptatem qui.

Corrupti necessitatibus voluptatibus ab iusto rerum eos est. Nesciunt et id aut velit sit adipisci laboriosam quis. Sint illum voluptates id nihil voluptatum. Ut magnam expedita culpa sit ut veritatis.

Aut perspiciatis sed rerum nam et voluptatem. Reprehenderit unde sit doloremque eum. Quis eos voluptas dolorem sapiente necessitatibus temporibus. Ea velit eaque amet optio veritatis doloribus. Et corrupti perferendis dolores laudantium quia.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.4%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (56) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
GameTheory's picture
GameTheory
98.9
6
dosk17's picture
dosk17
98.9
7
CompBanker's picture
CompBanker
98.9
8
DrApeman's picture
DrApeman
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”